BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 19453414)

  • 1. Preparation of genetically engineered A/H5N1 and A/H7N1 pandemic vaccine viruses by reverse genetics in a mixture of Vero and chicken embryo cells.
    Legastelois I; Garcia-Sastre A; Palese P; Tumpey TM; Maines TR; Katz JM; Vogel FR; Moste C
    Influenza Other Respir Viruses; 2007 May; 1(3):95-104. PubMed ID: 19453414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a new candidate H5N1 avian influenza virus for pre-pandemic vaccine production.
    Dong J; Matsuoka Y; Maines TR; Swayne DE; O'Neill E; Davis CT; Van-Hoven N; Balish A; Yu HJ; Katz JM; Klimov A; Cox N; Li DX; Wang Y; Guo YJ; Yang WZ; Donis RO; Shu YL
    Influenza Other Respir Viruses; 2009 Nov; 3(6):287-95. PubMed ID: 19903211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of H5N1 influenza vaccine viruses: influence of internal gene segments of avian and human origin on production and hemagglutinin content.
    Abt M; de Jonge J; Laue M; Wolff T
    Vaccine; 2011 Jul; 29(32):5153-62. PubMed ID: 21624413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of candidate human influenza vaccine strains in cell culture - rehearsing the European response to an H7N1 pandemic threat.
    Whiteley A; Major D; Legastelois I; Campitelli L; Donatelli I; Thompson CI; Zambon MC; Wood JM; Barclay WS
    Influenza Other Respir Viruses; 2007 Jul; 1(4):157-66. PubMed ID: 19432631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Vero-cell-adapted vaccine donor strain of influenza A virus generated by serial passages.
    Hu W; Zhang H; Han Q; Li L; Chen Y; Xia N; Chen Z; Shu Y; Xu K; Sun B
    Vaccine; 2015 Jan; 33(2):374-81. PubMed ID: 25448099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of a reassortant avian influenza virus H5N2 vaccine strain capable of protecting chickens against infection with Egyptian H5N1 and H9N2 viruses.
    Kandeil A; Moatasim Y; Gomaa MR; Shehata MM; El-Shesheny R; Barakat A; Webby RJ; Ali MA; Kayali G
    Vaccine; 2016 Jan; 34(2):218-224. PubMed ID: 26620838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of American-Lineage Influenza H5N2 Reassortant Vaccine Viruses for Pandemic Preparedness.
    Chen PL; Hu AY; Lin CY; Weng TC; Lai CC; Tseng YF; Cheng MC; Chia MY; Lin WC; Yeh CT; Su IJ; Lee MS
    Viruses; 2019 Jun; 11(6):. PubMed ID: 31212631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian viruses.
    Shi H; Liu XF; Zhang X; Chen S; Sun L; Lu J
    Vaccine; 2007 Oct; 25(42):7379-84. PubMed ID: 17870216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics.
    Subbarao K; Chen H; Swayne D; Mingay L; Fodor E; Brownlee G; Xu X; Lu X; Katz J; Cox N; Matsuoka Y
    Virology; 2003 Jan; 305(1):192-200. PubMed ID: 12504552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Engineering by reverse genetics and characterization of the new reassortant influenza virus strain H5N1].
    Zeberezhnyĭ AD; Grebennikova TV; Vorkunova GK; Yuzhakov AG; Kostina LV; Norkina SN; Aliper TI; Nepoklonov EA; Lvov DK
    Vopr Virusol; 2014; 59(6):23-7. PubMed ID: 25929032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cloned cDNA of A/swine/Iowa/15/1930 internal genes as a candidate backbone for reverse genetics vaccine against influenza A viruses.
    Lekcharoensuk P; Wiriyarat W; Petcharat N; Lekcharoensuk C; Auewarakul P; Richt JA
    Vaccine; 2012 Feb; 30(8):1453-9. PubMed ID: 22230579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of influenza vaccine strain A/Vietnam/1194/2004 (H5N1) growth with the neuraminidase packaging sequence from A/Puerto Rico/8/34.
    Pan W; Dong Z; Meng W; Zhang W; Li T; Li C; Zhang B; Chen L
    Hum Vaccin Immunother; 2012 Feb; 8(2):252-9. PubMed ID: 22426370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation of Influenza A Virus PA-X Decreases Pathogenicity in Chicken Embryos and Can Increase the Yield of Reassortant Candidate Vaccine Viruses.
    Hussain S; Turnbull ML; Wise HM; Jagger BW; Beard PM; Kovacikova K; Taubenberger JK; Vervelde L; Engelhardt OG; Digard P
    J Virol; 2019 Jan; 93(2):. PubMed ID: 30381488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and evaluation of an Influenza virus subtype H7N2 vaccine candidate for pandemic preparedness.
    Pappas C; Matsuoka Y; Swayne DE; Donis RO
    Clin Vaccine Immunol; 2007 Nov; 14(11):1425-32. PubMed ID: 17913860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines.
    Webby RJ; Perez DR; Coleman JS; Guan Y; Knight JH; Govorkova EA; McClain-Moss LR; Peiris JS; Rehg JE; Tuomanen EI; Webster RG
    Lancet; 2004 Apr; 363(9415):1099-103. PubMed ID: 15064027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Clade-Specific and Broadly Reactive Live Attenuated Influenza Virus Vaccines against Rapidly Evolving H5 Subtype Viruses.
    Boonnak K; Matsuoka Y; Wang W; Suguitan AL; Chen Z; Paskel M; Baz M; Moore I; Jin H; Subbarao K
    J Virol; 2017 Aug; 91(15):. PubMed ID: 28490598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potency of an inactivated avian influenza vaccine prepared from a non-pathogenic H5N1 reassortant virus generated between isolates from migratory ducks in Asia.
    Isoda N; Sakoda Y; Kishida N; Soda K; Sakabe S; Sakamoto R; Imamura T; Sakaguchi M; Sasaki T; Kokumai N; Ohgitani T; Saijo K; Sawata A; Hagiwara J; Lin Z; Kida H
    Arch Virol; 2008; 153(9):1685-92. PubMed ID: 18651092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of gene constellation and postreassortment amino acid change on the phenotypic features of H5 influenza virus reassortants.
    Rudneva IA; Timofeeva TA; Shilov AA; Kochergin-Nikitsky KS; Varich NL; Ilyushina NA; Gambaryan AS; Krylov PS; Kaverin NV
    Arch Virol; 2007; 152(6):1139-45. PubMed ID: 17294090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of reverse genetics-derived cold-adapted master donor virus A/Leningrad/134/17/57 (H2N2) and reassortants with H5N1 surface genes in a mouse model.
    Isakova-Sivak I; Chen LM; Bourgeois M; Matsuoka Y; Voeten JT; Heldens JG; van den Bosch H; Klimov A; Rudenko L; Cox NJ; Donis RO
    Clin Vaccine Immunol; 2014 May; 21(5):722-31. PubMed ID: 24648485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increase in viral yield in eggs and MDCK cells of reassortant H5N1 vaccine candidate viruses caused by insertion of 38 amino acids into the NA stalk.
    Zhang W; Xue T; Wu X; Zhang P; Zhao G; Peng D; Hu S; Wang X; Liu X; Liu W; Liu X
    Vaccine; 2011 Oct; 29(45):8032-41. PubMed ID: 21864614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.